Aubrey de Grey, Ph.D. Born London, England, 1963
B.A., M.A. and Ph.D., University of Cambridge, Cambridge, UK.
Employment 1985-1986: Sinclair Research
Employment 1986-1992: Man-Made Minions
Employment 1992-2006: Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK
Employment 2006-present: Chairman and Chief Science Officer, Methuselah Foundation
The central goal of my work is to expedite the development of a true cure for human aging. In my view, the main obstacle to developing such technology is the position of biogerontology at the boundary between basic science and medicine: the fundamental knowledge necessary to develop truly effective anti-aging medicine mostly exists, but the goal-directed frame of mind that is best suited to turning research findings into tools is very different from the curiosity-driven ethos that generated those findings in the first place. As a scientist with a training in an engineering discipline (computer science), I am unusually well placed to bridge this gap. I attempt to do so in three main ways: I do basic biogerontology research, I identify and promote specific technological approaches to the reversal (not merely the prevention) of various aspects of aging, and I argue in a wide range of fora (extending well beyond biologists) for the adoption of a more proactive approach to extending the healthy human lifespan sooner rather than later.
Speaking engagements: I give an average of 20-30 invited talks per year at scientific conferences and universities. My upcoming speaking engagements are listed here.
A list of my main publications is given here.
Michael Rae
is Dr. de Grey’s Research Assistant and popular science writer with a strong focus on health and aging. He is the author of five scientific articles and commentaries in peer-reviewed scientific journals. Much of his work with the Foundation has been devoted to elucidating the SENS platform for anti-aging biomedicine for a popular audience. His undergraduate minor was in biology. Between 1999 and early 2005, he worked in R&D in the nutraceutical industry, where he was instrumental in shifting company focus into novel molecules with the potential to impact primary and secondary aging.